Joshua B Cohen is Co-Chief Executive Officer of Amylyx Pharmaceuticals, Inc.. Currently has a direct ownership of 3.22 Million shares of AMLX, which is worth approximately $16 Million. The most recent transaction as insider was on Sep 30, 2024, when has been sold 18,589 shares (Common Stock) at a price of $3.2 per share, resulting in proceeds of $59,484. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 3.22M
0.55% 3M change
15.32% 12M change
Total Value Held $16 Million

Joshua B Cohen Transaction History

Date Transaction Value Shares Traded Shares Held Form
Sep 30 2024
SELL
Open market or private sale
$59,484 $3.2 p/Share
18,589 Reduced 0.57%
3,220,569 Common Stock
Sep 23 2024
BUY
Exercise of conversion of derivative security
$2,915 $1.57 p/Share
1,857 Added 0.06%
3,239,158 Common Stock
Sep 12 2024
BUY
Exercise of conversion of derivative security
$54,084 $1.57 p/Share
34,449 Added 1.05%
3,237,301 Common Stock
Apr 16 2024
BUY
Grant, award, or other acquisition
-
179,850 Added 5.32%
3,202,852 Common Stock
Mar 05 2024
SELL
Open market or private sale
$77,448 $18.73 p/Share
4,135 Reduced 0.14%
3,023,002 Common Stock
Feb 26 2024
BUY
Grant, award, or other acquisition
-
126,667 Added 4.02%
3,027,137 Common Stock
Jan 09 2024
SELL
Open market or private sale
$95,383 $16.33 p/Share
5,841 Reduced 0.2%
2,900,470 Common Stock
Nov 16 2023
BUY
Exercise of conversion of derivative security
$99,999 $1.57 p/Share
63,694 Added 2.14%
2,906,311 Common Stock
Mar 16 2023
SELL
Open market or private sale
$3,215,000 $32.15 p/Share
100,000 Reduced 3.46%
2,792,617 Common Stock
Mar 16 2023
BUY
Grant, award, or other acquisition
-
50,000 Added 1.73%
2,842,617 Common Stock
Jan 06 2023
BUY
Open market or private sale
$217,473 $36.44 p/Share
5,968 Added 0.21%
2,892,617 Common Stock
May 05 2022
BUY
Exercise of conversion of derivative security
$123,772 $0.37 p/Share
334,520 Added 10.35%
2,898,585 Common Stock
Jan 06 2022
BUY
Conversion of derivative security
-
4,870 Added 0.2%
2,489,065 Common Stock
Jan 06 2022
BUY
Grant, award, or other acquisition
-
75,000 Added 2.84%
2,564,065 Common Stock
JBC

Joshua B Cohen

Co-Chief Executive Officer
Cambridge, MA

Track Institutional and Insider Activities on AMLX

Follow Amylyx Pharmaceuticals, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells AMLX shares.

Notify only if

Insider Trading

Get notified when an Amylyx Pharmaceuticals, Inc. insider buys or sells AMLX shares.

Notify only if

News

Receive news related to Amylyx Pharmaceuticals, Inc.

Track Activities on AMLX